Cerivastatin and hypercholesterolemia reduce apoptosis of cardiomyocytes in guinea pig papillary muscle subjected to hypoxia/reoxygenation

Pharmacological Reports

Volumn 58, Issue 3, 2006, Pages 420-426

  Dworakowski, Rafał ^a   Dworakowska, Dorota ^a   Kocic, Ivan ^a   Wirth, Tomas ^b   Gruchała, Marcin ^a   Kamiński, Maciej ^a   Petrusewicz, Jacek ^a   Yla Herttuala, Seppo ^b   Rynkiewicz, Andrzej ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Apoptosis; Cerivastatin; Experimental hypoxia reoxygenation; Hypercholesterolemia

Indexed keywords

CERIVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG MECHANISM; GUINEA PIG; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE INJURY; HEART PAPILLARY MUSCLE; HYPERCHOLESTEROLEMIA; HYPOXIA; LOW DRUG DOSE; MALE; NICK END LABELING; NONHUMAN; REOXYGENATION;

EID: 33746360592     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bell RM, Yellon DM: Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol, 2003, 41, 508-515.
2. Calabresi L, Rossoni G, Gomaraschi M, Sisto F, Berti F, Franceschini G: High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ Res, 2003, 92, 330-337.
3. Conde K, Vergara-Jimenez M, Krause BR, Newton RS, Fernandez ML: Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J Lipid Res, 1996, 37, 2372-2382.
4. Dimmeler S, Haendeler J, Galle J, Zeiher AM: Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. A mechanistic clue to the 'response to injury' hypothesis. Circulation, 1997, 95, 1760-1763.
5. Eto M, Luscher TF: The cardioprotective effects of statins. Coron Artery Dis, 2004, 15, 243-245.
6. Girod WG, Jones SP, Sieber N, Aw TY, Lefer DJ: Effects of hypercholesterolemia on myocardial ischemia-reperfusion injury in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol, 1999, 19, 2776-2781.
7. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL: Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest, 1994, 94, 1621-1628.
8. Haunstetter A, Izumo S: Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res, 1998, 82, 1111-1129.
9. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM: Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol, 2005, 288, H971-976.
10. Hausenloy DJ, Yellon DM: New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res, 2004, 61, 448-460.
11. Jones SP, Trocha SD, Lefer DJ: Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. Arterioscler Thromb Vasc Biol, 2001, 21, 2059-2064.
12. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW: Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol, 1999, 33, 234-241.
13. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med, 2000, 6, 1004-1010.
14. Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 1998, 97, 1129-1135.
15. Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J, 2003, 326, 1423.
16. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ: Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation, 1999, 100, 178-184.
17. Lefer AM, Scalia R, Lefer DJ: Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res, 2001, 49, 281-287.
18. Lefer DJ, Scalia R, Jones SP, Sharp BR, Hoffmeyer MR, Farvid AR, Gibson MF, Lefer AM: HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. FASEB J, 2001, 15, 1454-1456.
19. McFarlane SI, Muniyappa R, Francisco R, Sowers JR: Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab, 2002, 87, 1451-1458.
20. Mensah K, Mocanu MM, Yellon DM: Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol, 2005, 45, 1287-1291.
21. Nofer JR, Levkau B, Wolinska I, Junker R, Fobker M, von Eckardstein A, Seedorf U, Assmann G: Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem, 2001, 276, 34480-34485.
22. Pulkkanen KJ, Laukkanen MO, Naarala J, Yla-Herttuala S: False-positive apoptosis signal in mouse kidney and liver detected with TUNEL assay. Apoptosis, 2000, 5, 329-333.
23. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB: The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation, 1977, 56, 786-794.
24. Tilton RG, Cole PA, Zions JD, Daugherty A, Larson KB, Sutera SP, Kilo C, Williamson JR: Increased ischemia-reperfusion injury to the heart associated with short-term, diet-induced hypercholesterolemia in rabbits. Circ Res, 1987, 60, 551-559.
25. Tong H, Chen W, Steenbergen C, Murphy E: Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res, 2000, 87, 309-315.
26. Ueda Y, Kitakaze M, Komamura K, Minamino T, Asanuma H, Sato H, Kuzuya T et al.: Pravastatin restored the infarct size-limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarction. J Am Coll Cardiol, 1999, 34, 2120-2125.
27. Verma S, Rao V, Weisel RD, Li SH, Fedak PW, Miriuka S, Li RK: Novel cardioprotective effects of pravastatin in human ventricular cardiomyocytes, subjected to hypoxia and reoxygenation: beneficial effects of statins independent of endothelial cells. J Surg Res, 2004, 119, 66-71.
28. Wang TD, Chen WJ, Su SS, Lo SC, Lin WW, Lee YT: Increased cardiomyocyte apoptosis following ischemia and reperfusion in diet-induced hypercholesterolemia: relation to Bcl-2 and Bax proteins and caspase-3 activity. Lipids, 2002, 37, 385-394.
29. Wayman NS, Ellis BL, Thiemermann C: Simvastatin reduces infarct size in a model of acute myocardial ischemia and reperfusion in the rat. Med Sci Monit, 2003, 9, BR155-159.
30. Zhao ZQ, Nakamura M, Wang NP, Wilcox JN, Shearer S, Ronson RS, Guyton RA, Vinten-Johansen J: Reperfusion induces myocardial apoptotic cell death. Cardiovasc Res, 2000, 45, 651-660.